CML
Conference Coverage
Inotuzumab / bosutinib treat R/R Ph+ ALL, CML in blast phase
Conference Coverage
Complementary medicine use common among patients on TKIs
GLASGOW – A survey of chronic myeloid leukemia patients taking tyrosine kinase inhibitors (TKIs) revealed that more than one-third were taking...
News
FDA clears test to monitor residual disease in CML
The system can quantitate the molecular response of patients receiving tyrosine kinase inhibitor therapy.
Feature
MD Anderson–led alliance seeks to advance leukemia drug development
The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.
News
Early switch to dasatinib offers clinical benefit to CML patients
SAN DIEGO—Early results of the DASCERN trial indicate that patients with chronic myeloid leukemia (CML) in chronic phase who have a suboptimal...
News
Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuation
SAN DIEGO—Preliminary trial results suggest re-treatment with dasatinib is feasible and safe for a second attempt at tyrosine kinase inhibitor (...
News
Health Canada approves two tests for CML patients
Health Canada has approved the use of two tests designed to detect BCR-ABL transcripts in patients with chronic myeloid leukemia (CML)—the MRDx®...
Conference Coverage
When is it CMML?
DUBROVNIK, CROATIA – Dr. Nadira Durakovic offers her tips for differentiating between CMML and other look-alike disorders.
News
FDA issues draft guidance on MRD
The U.S.
Conference Coverage
Optimizing use of TKIs in chronic leukemia
DUBROVNIK, CROATIA – Dr. Hagop M. Kantarjian offers tips for choosing the best TKI when treating patients with CML.
News
Optimizing use of TKIs in CML
DUBROVNIK, CROATIA—Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (...